ACORAI Presents Positive Results in 1,600-Patient CAPTURE-HF Study for its AI-Powered Non-Invasive Multi-Sensor Platform for Improved Heart Failure Patient Management
MINNEAPOLIS, Oct. 6, 2025 /PRNewswire/ — Acorai, a clinical-stage company pioneering non-invasive hemodynamic monitoring for heart failure management, this week announced topline results from the 1,600-patient CAPTURE-HF study (Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-Invasive Multi-sensor Device). Results were presented during a Late-Breaking Clinical Science session by Principal Investigator Andrew J. Sauer, M.D., Professor of Medicine at Saint Luke’s Kansas City, at the Heart Failure Society of America (HFSA) 2025 Annual Scientific Meeting in Minneapolis, Minnesota.
The prospective, two-phase study enrolled patients across 20 global sites to evaluate the accuracy, safety, and usability of Acorai’s device compared to the invasive right heart catheterization gold standard.
In patients with heart failure, Acorai’s non-invasive multi-sensor device demonstrated:
- Pulmonary Capillary Wedge Pressure (PCWP >15 mmHg): AUC 0.821, Sensitivity 86%, Specificity 53%, Negative Predictive Value (NPV) 90%
- Right Atrial Pressure (RAP >10 mmHg): AUC 0.852, Sensitivity 87%, Specificity 70%, NPV 97%
